Barclays
HELP

Barclays’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Barclays’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-862
Closed -$4.14K – 5407
2026
Q1 		$4.14K Hold
862
– – ﹤0.01% 4791
2025
Q4 		$7.05K Hold
862
– – ﹤0.01% 4964
2025
Q3 		$5.08K Hold
862
– – ﹤0.01% 5084
2025
Q2 		$7.23K Buy
+862
New +$6.27K ﹤0.01% 4938
2023
Q3 		– Sell
-1,584
Closed -$22.8K – 4618
2023
Q2 		$22.8K Hold
1,584
– – ﹤0.01% 4112
2023
Q1 		$23.2K Buy
+1,584
New +$25.7K ﹤0.01% 4629
2022
Q3 		– Sell
-11,316
Closed -$236K – 4854
2022
Q2 		$236K Hold
11,316
– – ﹤0.01% 3335
2022
Q1 		$353K Buy
+11,316
New +$413K ﹤0.01% 3109

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Barclays's HELP Position: Q2 2026 in Review

Barclays sold out of Helus Pharma Inc. Common Stock (HELP) in Q2 2026, closing a stake of 862 shares — an estimated $4.14K sold.

Barclays first reported a position in HELP in Q1 2022 and held it in 8 quarters. The position peaked at $353K in Q1 2022. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • Barclays reported no remaining Helus Pharma Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Barclays sold 862 Helus Pharma Inc. Common Stock shares in Q2 2026, an estimated $4.14K.
  • Barclays first reported a position in Helus Pharma Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Barclays's Helus Pharma Inc. Common Stock position peaked at $353K in Q1 2022.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.